Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group, Phase 3 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1)

NCT03496012 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT03496012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03496012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group, Phase 3 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1)
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Completed
Start date
December 11, 2017
Completion date
December 1, 2020
Enrollment
169 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

choroideremia